Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Opdivo symbols : Bmy save search
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.33%
H: 1.02%
C: 0.48%
opdivo treatment trial advanced plus
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
Published: 2024-02-07 (Crawled : 13:30) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.14%
H: 0.35%
C: -1.12%
lung opdivo cancer cell
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)
Published: 2023-12-07 (Crawled : 18:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.84%
H: 1.39%
C: -0.28%
opdivo trial plus
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab)
Published: 2023-12-05 (Crawled : 16:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.36%
H: 1.2%
C: 0.86%
drug opdivo review food application
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
Published: 2023-10-17 (Crawled : 00:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.03%
H: 0.87%
C: 0.38%
lung opdivo cancer cell trial benefits
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
Published: 2023-10-17 (Crawled : 00:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.03%
H: 0.87%
C: 0.38%
lung opdivo cancer cell trial
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo
Published: 2023-09-22 (Crawled : 13:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.42%
H: 0.21%
C: -0.72%
opdivo
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2023-09-11 (Crawled : 14:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.12%
H: 1.11%
C: 0.1%
lung opdivo cancer cell treatment trial plus show
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
Published: 2023-07-21 (Crawled : 12:20) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.19%
H: 1.41%
C: 1.24%
melanoma chmp opdivo approval positive treatment
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and PFS Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial
Published: 2023-07-11 (Crawled : 12:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.26%
H: 0.96%
C: 0.75%
opdivo trial
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer
Published: 2023-06-29 (Crawled : 13:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.5%
H: 1.06%
C: 0.36%
lung opdivo approval cancer cell treatment
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®
Published: 2023-05-24 (Crawled : 20:00) - prnewswire.com
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.81%
H: 0.32%
C: -0.59%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -6.18%
H: 0.0%
C: -6.64%
opdivo update sapphire therapeutics study
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial
Published: 2023-03-30 (Crawled : 15:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.29%
H: 0.22%
C: -0.26%
lung opdivo cancer cell trial benefits
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
Published: 2023-03-23 (Crawled : 13:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.52%
H: 0.46%
C: -0.9%
BBIO | $25.03 -1.69% -1.76% 0
|
Health Technology
|
| O: 0.62%
H: 5.65%
C: 5.11%
bbp-398 opdivo lung pharma cancer trial phase 1
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….
Published: 2023-02-28 (Crawled : 16:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.27%
H: 0.2%
C: -1.2%
drug application opdivo license food nivolumab
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Published: 2023-02-13 (Crawled : 00:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.23% 690
|
Health Technology
|
| O: -1.37%
H: 0.69%
C: 0.51%
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.03%
H: 1.69%
C: 1.32%
EXEL | $23.515 -0.82% 100K
|
Health Technology
|
| O: -0.68%
H: 1.66%
C: 1.49%
opdivo renal trial cell carcinoma nivolumab
Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS)
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 0.24%
H: 2.12%
C: 1.61%
treatment opdivo nivolumab
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma
Published: 2022-07-29 (Crawled : 12:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: -0.33%
H: 0.27%
C: -0.9%
treatment opdivo renal trial plus update cell carcinoma nivolumab
Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab)
Published: 2022-06-06 (Crawled : 12:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
opdivo trial plus phase 3 nivolumab
Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2022-06-06 (Crawled : 12:00) - biospace.com/
BMY | $46.72 -4.38% 2M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
treatment opdivo trial plus cancer phase 3 nivolumab
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
BOF | $1.915 63.68% 620K
|
AMST | $3.13 56.5% 500K
|
Technology Services
ACON | $0.3595 24.83% 3.5M
|
n/a
ILAG | $0.669 23.89% 13M
|
CDTX | News | $14.57 18.55% 330K
|
Health Technology
ULBI M | $10.12 15.92% 120K
|
Producer Manufacturing
LRHC | $1.79 11.88% 3K
|
n/a
AIXI | $1.34 8.94% 42K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.